Full video transcriptClick to expand
Auto-generated transcript of @laurenferrell777's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00A little update for y'all. I've been off of ozimpic. This is the
- 0:05second full week and
- 0:08I'm not gonna lie
- 0:09I'm really hungry
- 0:11Like all the time just hungry. So I think I've gained
- 0:18Like one and a half or two pounds. I did go like on a getaway trip with my husband
- 0:26To the casino and I had like a lot of like sugary drinks. I don't normally drink
- 0:32and I ate like fried food and
- 0:36Pizza stuff like that. So I'm not too worried about it
- 0:42But I just wanted to update you guys
Stopping Ozempic: what week two off semaglutide actually looks like
Quick answer
Semaglutide has a half-life of approximately seven days, meaning appetite suppression and gastric motility effects diminish progressively over several weeks after the last dose. The return of hunger Lauren describes at two weeks post-cessation is consistent with partial drug clearance and is supported by pharmacokinetic data and clinical trial follow-up results. Weight changes at this stage are likely a mix of fluid shifts from dietary changes and early caloric intake increases rather than meaningful fat regain.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Stopping Ozempic: what week two off semaglutide actually looks like, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Stopping Ozempic: what week two off semaglutide actually looks like" from LAUREN FERRELL. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semaglutide has a half-life of approximately seven days, meaning appetite suppression and gastric motility effects diminish progressively over several weeks after the last dose.
The reason this review is not generic is the source wording and the canonical claim label "glp1 ozempic update week two off of ozempic." In this clip, the useful excerpt is: "A little update for y'all." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Semaglutide has a half-life of approximately seven days, meaning appetite suppression and gastric motility effects diminish progressively over several weeks after the last dose.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Semaglutide has a half-life of approximately seven days, meaning appetite suppression and gastric motility effects diminish progressively over several weeks after the last dose. The return of hunger Lauren describes at two weeks post-cessation is consistent with partial drug clearance and is supported by pharmacokinetic data and clinical trial follow-up results. Weight changes at this stage are likely a mix of fluid shifts from dietary changes and early caloric intake increases rather than meaningful fat regain.
- Semaglutide has a half-life of roughly 7 days, so appetite suppression fades progressively over 5-7 weeks after stopping, not immediately.
- Wilding et al. (2022, NEJM) found participants regained two-thirds of their lost weight within one year of stopping semaglutide, driven primarily by appetite return.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Semaglutide has a half-life of roughly 7 days, so appetite suppression fades progressively over 5-7 weeks after stopping, not immediately.
- Wilding et al. (2022, NEJM) found participants regained two-thirds of their lost weight within one year of stopping semaglutide, driven primarily by appetite return.
- Scale weight fluctuations of 1-2 pounds over days are largely fluid shifts, especially after alcohol and high-sodium meals, not reliable indicators of fat gain.
- Rubino et al. (2023, Diabetes, Obesity and Metabolism) confirmed that hunger, not metabolic slowdown, is the dominant driver of post-GLP-1 weight regain.
- Stopping a GLP-1 medication without provider input increases rebound risk. Tapering protocols and behavioral support strategies exist and should be part of any discontinuation plan.
- Lauren's self-report is consistent with what clinical data predicts at two weeks post-cessation. Her video contains no inaccurate health claims.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @laurenferrell777 actually say?
Lauren gave a straightforward two-week update after stopping semaglutide. She said she's "really hungry, like all the time just hungry" and thinks she's gained "one and a half or two pounds." She also noted the weight bump coincided with a casino trip involving sugary drinks, fried food, and pizza, and she acknowledged that context directly. No dramatic claims, no miracle language. Just an honest personal report.
That kind of transparency is actually rare in GLP-1 content. Most creators either oversell the drug or catastrophize stopping it. Lauren is doing neither. She's describing what many clinicians would predict: appetite returns, and caloric intake tends to follow. The casino trip confounds her weight number, and she seems to know that.
Does the science back this up?
Yes, the return of hunger after stopping semaglutide is well-documented. This is not anecdote, it is the expected pharmacological outcome.
Semaglutide works partly by slowing gastric emptying and acting on hypothalamic appetite-regulating circuits. When the drug clears, those effects reverse. Wilding et al. (2022, New England Journal of Medicine) followed participants who stopped semaglutide after a 68-week trial and found that two-thirds of the weight lost was regained within one year. The mechanism is not mysterious: the drug suppresses hunger signals, and stopping the drug unsuppresses them.
A 2023 analysis by Rubino et al. (Diabetes, Obesity and Metabolism) confirmed that weight regain after GLP-1 cessation is largely driven by the return of appetite rather than metabolic changes alone. Lauren is describing exactly that rebound in real time, two weeks in, before most of the regain would even be measurable.
One and a half to two pounds in two weeks is within normal daily fluctuation range, so the number itself may not be meaningful yet.
What did they get wrong (or right)?
Lauren got the core experience right. Hunger returning after stopping semaglutide is not a personal failure or a sign something went wrong. It is the drug behaving exactly as expected when absent.
What she did not say, and probably should know, is that this hunger is not the same as it was before she ever started the medication. Research suggests GLP-1 receptor agonists may reset some appetite signaling over time, but the effect is not permanent without the drug present. Once semaglutide clears, which takes roughly five to seven weeks given its half-life of approximately one week, most people are back to baseline hunger levels or close to it.
She also correctly identified that the casino trip is a confounding variable. That kind of dietary self-awareness matters. The two pounds likely reflects water retention from sodium and alcohol as much as fat gain. She is not wrong to be unconcerned about it.
There is nothing misleading in this video. No false equivalencies, no dangerous advice. She is just reporting her experience, and her experience matches what the clinical literature predicts.
What should you actually know?
Stopping semaglutide without a plan is where things tend to go sideways. The hunger Lauren describes is physiologically real, not a willpower problem. GLP-1 medications work while you take them. That is not a character flaw of the drug. It is how most chronic condition medications work.
If you are considering stopping semaglutide, a few things are worth understanding. First, the appetite return is often rapid, within days to weeks of stopping. Second, weight regain in the Wilding 2022 trial averaged about 6.9% of body weight within one year of discontinuation. Third, behavioral strategies like consistent protein intake, structured meal timing, and hunger journaling can buffer some of that rebound, though they do not fully replicate the drug's effect.
Anyone stopping a GLP-1 medication should talk to a licensed provider first. There are clinical protocols for tapering or transitioning that can reduce rebound risk. Stopping cold because of cost, side effects, or a break from routine is common, but it should be a supervised decision when possible.
Lauren's video is a useful real-world data point. It is not a guide for what to do.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
LAUREN FERRELL · TikTok creator
2.2K views on this video
Ozempic update! Week two off of ozempic
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about semaglutide has a half-life of roughly 7 days, so appetite?
Semaglutide has a half-life of roughly 7 days, so appetite suppression fades progressively over 5-7 weeks after stopping, not immediately.
What does the video say about wilding et al. (2022, nejm) found participants regained two-thirds of?
Wilding et al. (2022, NEJM) found participants regained two-thirds of their lost weight within one year of stopping semaglutide, driven primarily by appetite return.
What does the video say about scale weight fluctuations of 1-2 pounds over days?
Scale weight fluctuations of 1-2 pounds over days are largely fluid shifts, especially after alcohol and high-sodium meals, not reliable indicators of fat gain.
What does the video say about rubino et al. (2023, diabetes, obesity?
Rubino et al. (2023, Diabetes, Obesity and Metabolism) confirmed that hunger, not metabolic slowdown, is the dominant driver of post-GLP-1 weight regain.
What does the video say about stopping a glp-1 medication without provider input increases rebound risk.?
Stopping a GLP-1 medication without provider input increases rebound risk. Tapering protocols and behavioral support strategies exist and should be part of any discontinuation plan.
What does the video say about lauren's self-report?
Lauren's self-report is consistent with what clinical data predicts at two weeks post-cessation. Her video contains no inaccurate health claims.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by LAUREN FERRELL, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.